MA39164B1 - Forme de sel cristalline de (s)-(2-(6-chloro-7-méthyl-1 h-benzo[d]imidazol- 2-yl)-2-méthylpyrrolidin-1-yl)(5-méthoxy-2-(2h-1,2,3-triazol-2-yl)phényl)méthanone comme antagoniste des récepteurs à l'oréxine - Google Patents
Forme de sel cristalline de (s)-(2-(6-chloro-7-méthyl-1 h-benzo[d]imidazol- 2-yl)-2-méthylpyrrolidin-1-yl)(5-méthoxy-2-(2h-1,2,3-triazol-2-yl)phényl)méthanone comme antagoniste des récepteurs à l'oréxineInfo
- Publication number
- MA39164B1 MA39164B1 MA39164A MA39164A MA39164B1 MA 39164 B1 MA39164 B1 MA 39164B1 MA 39164 A MA39164 A MA 39164A MA 39164 A MA39164 A MA 39164A MA 39164 B1 MA39164 B1 MA 39164B1
- Authority
- MA
- Morocco
- Prior art keywords
- methylpyrrolidin
- methanone
- triazol
- imidazol
- benzo
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4192—1,2,3-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Anesthesiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
La présente invention concerne une forme cristalline de chlorhydrate de (s)-(2-(6-chloro-7-méthyl-1 h-benzo[d]imidazol- 2-yl)-2-méthylpyrrolidin-1-yl)(5-méthoxy-2-(2h-1,2,3-triazol-2-yl)phényl)méthanone, des procédés de préparation associés, des compositions pharmaceutiques contenant ladite forme cristalline et son utilisation comme médicament, particulièrement comme antagoniste des récepteurs à l'oréxine.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IB2013060595 | 2013-12-03 | ||
PCT/IB2014/066509 WO2015083071A1 (fr) | 2013-12-03 | 2014-12-02 | Forme de sel cristalline de (s)-(2-(6-chloro-7-méthyl-1 h-benzo[d]imidazol- 2-yl)-2-méthylpyrrolidin-1-yl)(5-méthoxy-2-(2h-1,2,3-triazol-2-yl)phényl)méthanone comme antagoniste des récepteurs à l'oréxine |
Publications (2)
Publication Number | Publication Date |
---|---|
MA39164A1 MA39164A1 (fr) | 2017-08-31 |
MA39164B1 true MA39164B1 (fr) | 2019-03-29 |
Family
ID=52282787
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA39164A MA39164B1 (fr) | 2013-12-03 | 2014-12-02 | Forme de sel cristalline de (s)-(2-(6-chloro-7-méthyl-1 h-benzo[d]imidazol- 2-yl)-2-méthylpyrrolidin-1-yl)(5-méthoxy-2-(2h-1,2,3-triazol-2-yl)phényl)méthanone comme antagoniste des récepteurs à l'oréxine |
Country Status (32)
Country | Link |
---|---|
US (2) | US9790208B2 (fr) |
EP (1) | EP3077390B1 (fr) |
JP (1) | JP6091716B2 (fr) |
KR (1) | KR101839716B1 (fr) |
CN (1) | CN105793258B (fr) |
AU (1) | AU2014358743B2 (fr) |
CA (1) | CA2929720C (fr) |
CL (1) | CL2016001348A1 (fr) |
CY (1) | CY1119687T1 (fr) |
DK (1) | DK3077390T3 (fr) |
EA (1) | EA030109B1 (fr) |
ES (1) | ES2651508T3 (fr) |
HK (1) | HK1225736B (fr) |
HR (1) | HRP20171772T1 (fr) |
HU (1) | HUE034656T2 (fr) |
IL (1) | IL245922B (fr) |
LT (1) | LT3077390T (fr) |
MA (1) | MA39164B1 (fr) |
MX (1) | MX362701B (fr) |
MY (1) | MY176244A (fr) |
NO (1) | NO3077390T3 (fr) |
NZ (1) | NZ721493A (fr) |
PH (1) | PH12016500989B1 (fr) |
PL (1) | PL3077390T3 (fr) |
PT (1) | PT3077390T (fr) |
SA (1) | SA516371248B1 (fr) |
SG (1) | SG11201604541WA (fr) |
SI (1) | SI3077390T1 (fr) |
TW (1) | TWI636982B (fr) |
UA (1) | UA119151C2 (fr) |
WO (1) | WO2015083071A1 (fr) |
ZA (1) | ZA201604501B (fr) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI570120B (zh) | 2012-06-04 | 2017-02-11 | 艾克泰聯製藥有限公司 | 苯并咪唑脯胺酸衍生物 |
UA119151C2 (uk) * | 2013-12-03 | 2019-05-10 | Ідорсія Фармасьютікалз Лтд | КРИСТАЛІЧНА СОЛЬОВА ФОРМА (S)-(2-(6-ХЛОР-7-МЕТИЛ-1H-БЕНЗО[d]ІМІДАЗОЛ-2-ІЛ)-2-МЕТИЛПІРОЛІДИН-1-ІЛ)(5-МЕТОКСИ-2-(2H-1,2,3-ТРИАЗОЛ-2-ІЛ)ФЕНІЛ)МЕТАНОНУ ЯК АНТАГОНІСТ ОРЕКСИНОВОГО РЕЦЕПТОРА |
DK3077389T3 (da) | 2013-12-03 | 2017-11-13 | Idorsia Pharmaceuticals Ltd | Krystallinsk form af (s)-(2-(6-chlor-7-methyl-1h-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1-yl)(5-methoxy-2-(2h-1,2,3-triazol-2-yl)phenyl)methanon og dens anvendelse som orexinreceptorantagonister |
CN105873921B (zh) | 2013-12-04 | 2019-03-15 | 爱杜西亚药品有限公司 | 苯并咪唑-脯氨酸衍生物的用途 |
PL3619199T3 (pl) | 2017-05-03 | 2021-12-20 | Idorsia Pharmaceuticals Ltd | Wytwarzanie pochodnych kwasu 2-([1,2,3]triazol-2-ilo)-benzoesowego |
IL297234A (en) | 2020-04-19 | 2022-12-01 | Idorsia Pharmaceuticals Ltd | Medical use of deridorxant |
CN115925699B (zh) * | 2022-02-25 | 2023-10-03 | 南京知和医药科技有限公司 | 具有镇痛活性的稠环化合物及其制备方法与用途 |
CN117736193A (zh) * | 2023-12-19 | 2024-03-22 | 南京知和医药科技有限公司 | 一种氘代稠环化合物及其制备方法与用途 |
Family Cites Families (56)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3282927A (en) | 1964-05-21 | 1966-11-01 | Bristol Myers Co | 5-phenyl-4-thiazolylpenicillins |
AU2001272476A1 (en) | 2000-06-16 | 2001-12-24 | Smithkline Beecham Plc | Piperidines for use as orexin receptor antagonists |
MXPA03003039A (es) | 2000-10-06 | 2003-10-15 | Neurogen Corp | Derivados de indola y bencimidazola como moduladores del receptor crf. |
ATE286897T1 (de) | 2000-11-28 | 2005-01-15 | Smithkline Beecham Plc | Morpholinderivate als antagonisten an orexinrezeptoren |
EP1435955A2 (fr) | 2001-05-05 | 2004-07-14 | SmithKline Beecham P.L.C. | Derives d'amines cycliques n-aroyl utilises comme antagonistes du recepteur d'orexine |
KR20030096348A (ko) | 2001-05-05 | 2003-12-24 | 스미스클라인비이참피이엘시이 | N-아로일 시클릭 아민 |
GB0115862D0 (en) | 2001-06-28 | 2001-08-22 | Smithkline Beecham Plc | Compounds |
JP4399256B2 (ja) * | 2001-06-28 | 2010-01-13 | スミスクライン ビーチャム ピー エル シー | オレキシン受容体アンタゴニストとしてのn−アロイル環状アミン誘導体 |
GB0124463D0 (en) | 2001-10-11 | 2001-12-05 | Smithkline Beecham Plc | Compounds |
GB0127145D0 (en) | 2001-11-10 | 2002-01-02 | Smithkline Beecham | Compounds |
GB0130335D0 (en) | 2001-12-19 | 2002-02-06 | Smithkline Beecham Plc | Compounds |
GB0130393D0 (en) | 2001-12-19 | 2002-02-06 | Smithkline Beecham Plc | Compounds |
AU2003262516A1 (en) | 2002-09-18 | 2004-04-08 | Glaxo Group Limited | N-aroyl cyclic amines as orexin receptor antagonists |
GB0225944D0 (en) | 2002-11-06 | 2002-12-11 | Glaxo Group Ltd | Novel compounds |
GB0225938D0 (en) | 2002-11-06 | 2002-12-11 | Glaxo Group Ltd | Novel compounds |
GB0225884D0 (en) | 2002-11-06 | 2002-12-11 | Glaxo Group Ltd | Novel compounds |
PT1751111E (pt) | 2004-03-01 | 2015-04-01 | Actelion Pharmaceuticals Ltd | Derivados de 1,2,3,4-tetrahidroisoquinolina substituída |
BRPI0708913A2 (pt) | 2006-03-15 | 2011-06-14 | Actelion Pharmaceuticals Ltd | uso de compostos derivados de tetraidroisoquinolina para aumentar a funÇço da memària |
WO2007135527A2 (fr) * | 2006-05-23 | 2007-11-29 | Pfizer Products Inc. | Composés de benzimidazolyle |
RU2447070C2 (ru) | 2006-08-15 | 2012-04-10 | Актелион Фармасьютиклз Лтд | Соединения азетидина в качестве антагонистов рецептора орексина |
EP2079690B1 (fr) | 2006-09-29 | 2010-09-15 | Actelion Pharmaceuticals Ltd. | Derives du 3-aza-bicyclo[3.1.0]hexane |
PE20081229A1 (es) | 2006-12-01 | 2008-08-28 | Merck & Co Inc | Antagonistas de receptor de orexina de diazepam sustituido |
CL2007003827A1 (es) | 2006-12-28 | 2008-09-26 | Actelion Pharmaceuticals Ltd | Compuestos derivados de n-(2-aza-biciclo(3.1.0)hex-3-ilmetil)amida; y su uso para prevenir o tratar la depresion, neurosis, esquizofrenia, ansiedad, adicciones, epilepsia, dolor, enfermedades cardiacas, entre otras. |
WO2008087611A2 (fr) | 2007-01-19 | 2008-07-24 | Actelion Pharmaceuticals Ltd | Dérivés de pyrrolidine et de piperidine |
CL2008000836A1 (es) | 2007-03-26 | 2008-11-07 | Actelion Pharmaceuticals Ltd | Compuestos derivados de tiazolidina, antagonistas del receptor de orexina; composicion farmaceutica que los comprende; y su uso en el tratamiento de neurosis emocional, depresion grave, trastornos psicoticos, alzheimer, parkinson, dolor, entre otras. |
CN101711247A (zh) | 2007-05-14 | 2010-05-19 | 埃科特莱茵药品有限公司 | 2-环丙基-噻唑衍生物 |
EP2150115B1 (fr) | 2007-05-23 | 2013-09-18 | Merck Sharp & Dohme Corp. | Antagonistes du récepteur de la cyclopropylpyrrolidine orexine |
CA2691373A1 (fr) | 2007-07-03 | 2009-01-08 | Actelion Pharmaceuticals Ltd | Composes 3-aza-bicyclo[3.3.0]octane |
GB0712888D0 (en) | 2007-07-03 | 2007-08-15 | Glaxo Group Ltd | Novel compounds |
US20090022670A1 (en) | 2007-07-03 | 2009-01-22 | Giuseppe Alvaro | Novel compounds |
ATE493386T1 (de) | 2007-07-27 | 2011-01-15 | Actelion Pharmaceuticals Ltd | Trans-3-aza-bicyclo-ä3.1.0ü-hexan-derivate |
CA2693820A1 (fr) | 2007-07-27 | 2009-02-05 | Actelion Pharmaceuticals Ltd | Derives de 2-aza-bicyclo[3.3.0]octane |
WO2009040730A2 (fr) | 2007-09-24 | 2009-04-02 | Actelion Pharmaceuticals Ltd | Pyrrolidines et pipéridines en tant qu'antagonistes du récepteur de l'orexine |
PE20091010A1 (es) | 2007-10-10 | 2009-08-08 | Actelion Pharmaceuticals Ltd | Derivados de tetrahidroquinolina |
US8236801B2 (en) | 2008-02-21 | 2012-08-07 | Actelion Pharmaceuticals Ltd. | 2-aza-bicyclo[2.2.1]heptane derivatives |
GB0806536D0 (en) | 2008-04-10 | 2008-05-14 | Glaxo Group Ltd | Novel compounds |
CN102083827A (zh) | 2008-07-07 | 2011-06-01 | 埃科特莱茵药品有限公司 | 作为食欲素受体拮抗剂的噻唑烷化合物 |
WO2010038200A1 (fr) | 2008-10-01 | 2010-04-08 | Actelion Pharmaceuticals Ltd | Composés d'oxazolidine utilisables en tant qu'antagonistes des récepteurs à orexine |
EP2358712A1 (fr) | 2008-11-26 | 2011-08-24 | Glaxo Group Limited | Dérivés de la pipéridine utiles en tant qu antagonistes du récepteur de l orexine |
JP2012509912A (ja) | 2008-11-26 | 2012-04-26 | グラクソ グループ リミテッド | 新規の化合物 |
WO2010060470A1 (fr) | 2008-11-26 | 2010-06-03 | Glaxo Group Limited | Dérivés de la pipéridine utiles en tant qu’antagonistes du récepteur de l’orexine |
MX2011005799A (es) | 2008-12-02 | 2011-06-20 | Glaxo Group Ltd | Derivados de n{[(1r,4s,6r)-3-(2-piridinilcarbonil)-3-azabiciclo[4. 1.0]hept-4-il]metil}-2-heteroarilamina y sus usos. |
US20100144760A1 (en) | 2008-12-02 | 2010-06-10 | Giuseppe Alvaro | Novel compounds |
GB0823467D0 (en) * | 2008-12-23 | 2009-01-28 | Glaxo Group Ltd | Novel Compounds |
SG175026A1 (en) | 2009-04-24 | 2011-11-28 | Glaxo Group Ltd | 3 -azabicyclo [4.1.0] heptanes used as orexin antagonists |
TW201209037A (en) | 2010-08-24 | 2012-03-01 | Actelion Pharmaceuticals Ltd | Proline sulfonamide derivatives as orexin receptor antagonists |
CN103201261A (zh) | 2010-11-10 | 2013-07-10 | 埃科特莱茵药品有限公司 | 用作为食欲素受体拮抗剂的内酰胺衍生物 |
ES2541531T3 (es) | 2011-02-18 | 2015-07-21 | Actelion Pharmaceuticals Ltd. | Nuevos derivados de pirazol e imidazol útiles como antagonistas de orexina |
WO2013068935A1 (fr) | 2011-11-08 | 2013-05-16 | Actelion Pharmaceuticals Ltd | Dérivés de 2-(1,2,3-triazol-2-yl)benzamide et de 3-(1,2,3-triazol-2-yl)picolinamide en tant qu'antagonistes des récepteurs d'oréxine |
DK2838900T3 (da) | 2012-04-17 | 2019-10-14 | Gilead Sciences Inc | Forbindelser og fremgangsmåder til antiviral behandling |
TWI570120B (zh) * | 2012-06-04 | 2017-02-11 | 艾克泰聯製藥有限公司 | 苯并咪唑脯胺酸衍生物 |
CA2885180C (fr) | 2012-10-10 | 2021-03-02 | Actelion Pharmaceuticals Ltd | Antagonistes des recepteurs de l'orexine, qui sont des derives [ortho bi (hetero )aryl]-[2-(meta bi (hetero )aryl)-pyrrolidin-1-yl]-methanone |
CN105051040A (zh) | 2013-03-12 | 2015-11-11 | 埃科特莱茵药品有限公司 | 作为食欲素受体拮抗剂的氮杂环丁烷酰胺衍生物 |
DK3077389T3 (da) | 2013-12-03 | 2017-11-13 | Idorsia Pharmaceuticals Ltd | Krystallinsk form af (s)-(2-(6-chlor-7-methyl-1h-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1-yl)(5-methoxy-2-(2h-1,2,3-triazol-2-yl)phenyl)methanon og dens anvendelse som orexinreceptorantagonister |
UA119151C2 (uk) * | 2013-12-03 | 2019-05-10 | Ідорсія Фармасьютікалз Лтд | КРИСТАЛІЧНА СОЛЬОВА ФОРМА (S)-(2-(6-ХЛОР-7-МЕТИЛ-1H-БЕНЗО[d]ІМІДАЗОЛ-2-ІЛ)-2-МЕТИЛПІРОЛІДИН-1-ІЛ)(5-МЕТОКСИ-2-(2H-1,2,3-ТРИАЗОЛ-2-ІЛ)ФЕНІЛ)МЕТАНОНУ ЯК АНТАГОНІСТ ОРЕКСИНОВОГО РЕЦЕПТОРА |
CN105873921B (zh) | 2013-12-04 | 2019-03-15 | 爱杜西亚药品有限公司 | 苯并咪唑-脯氨酸衍生物的用途 |
-
2014
- 2014-02-12 UA UAA201607115A patent/UA119151C2/uk unknown
- 2014-12-02 NO NO14824108A patent/NO3077390T3/no unknown
- 2014-12-02 LT LTEP14824108.6T patent/LT3077390T/lt unknown
- 2014-12-02 US US15/101,832 patent/US9790208B2/en active Active
- 2014-12-02 EA EA201600436A patent/EA030109B1/ru not_active IP Right Cessation
- 2014-12-02 PT PT148241086T patent/PT3077390T/pt unknown
- 2014-12-02 WO PCT/IB2014/066509 patent/WO2015083071A1/fr active Application Filing
- 2014-12-02 EP EP14824108.6A patent/EP3077390B1/fr active Active
- 2014-12-02 MX MX2016007216A patent/MX362701B/es active IP Right Grant
- 2014-12-02 TW TW103141830A patent/TWI636982B/zh active
- 2014-12-02 NZ NZ721493A patent/NZ721493A/en unknown
- 2014-12-02 HU HUE14824108A patent/HUE034656T2/hu unknown
- 2014-12-02 ES ES14824108.6T patent/ES2651508T3/es active Active
- 2014-12-02 AU AU2014358743A patent/AU2014358743B2/en active Active
- 2014-12-02 KR KR1020167017678A patent/KR101839716B1/ko active IP Right Grant
- 2014-12-02 PL PL14824108T patent/PL3077390T3/pl unknown
- 2014-12-02 SI SI201430453T patent/SI3077390T1/sl unknown
- 2014-12-02 MY MYPI2016701995A patent/MY176244A/en unknown
- 2014-12-02 DK DK14824108.6T patent/DK3077390T3/da active
- 2014-12-02 SG SG11201604541WA patent/SG11201604541WA/en unknown
- 2014-12-02 CA CA2929720A patent/CA2929720C/fr active Active
- 2014-12-02 JP JP2016536106A patent/JP6091716B2/ja active Active
- 2014-12-02 MA MA39164A patent/MA39164B1/fr unknown
- 2014-12-02 CN CN201480065749.2A patent/CN105793258B/zh active Active
-
2016
- 2016-05-26 PH PH12016500989A patent/PH12016500989B1/en unknown
- 2016-05-30 IL IL24592216A patent/IL245922B/en active IP Right Grant
- 2016-06-01 SA SA516371248A patent/SA516371248B1/ar unknown
- 2016-06-02 CL CL2016001348A patent/CL2016001348A1/es unknown
- 2016-07-01 ZA ZA2016/04501A patent/ZA201604501B/en unknown
- 2016-12-14 HK HK16114201A patent/HK1225736B/zh unknown
-
2017
- 2017-09-12 US US15/702,281 patent/US10023560B2/en active Active
- 2017-11-16 HR HRP20171772TT patent/HRP20171772T1/hr unknown
- 2017-12-12 CY CY20171101302T patent/CY1119687T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA39164A1 (fr) | Forme de sel cristalline de (s)-(2-(6-chloro-7-méthyl-1 h-benzo[d]imidazol- 2-yl)-2-méthylpyrrolidin-1-yl)(5-méthoxy-2-(2h-1,2,3-triazol-2-yl)phényl)méthanone comme antagoniste des récepteurs à l'oréxine | |
MA39163A1 (fr) | Forme cristalline de (s)-(2-(6-chloro-7-methyl-1h-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1 -yl)(5-methoxy-2-(2h-1,2,3-triazol-2-yl)phenyl)methanone et utilisation de celle-ci en tant qu'antagonistes des recepteurs de l'orexine | |
MA39211B1 (fr) | Composés tricycliques comme agents anti-cancers | |
UA100877C2 (ru) | Замещенные спироциклические производные пиперидина как лиганды рецепторов гистамина-3 (h3) | |
PH12015501247B1 (en) | Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity | |
PH12017501424B1 (en) | Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity | |
MA35107B1 (fr) | Composition pharmaceutique antihypertensive | |
PE20151535A1 (es) | Derivado de dihidropiridazin-3,5-diona | |
EA201692220A1 (ru) | Твердые формы противовирусного соединения | |
IN2015DN00538A (fr) | ||
EA201590823A1 (ru) | 6-((s)-1-{1-[5-(2-гидроксиэтокси)пиридин-2-ил]-1h-пиразол-3-ил}этил)-3h-1,3-бензотиазол-2-он в качестве антагониста tarp-гамма 8-зависимого ampa-рецептора | |
MX2017015047A (es) | Compuestos que tienen actividad antagonista del receptor muscarinico y actividad agonista del receptor beta2 adrenergico. | |
MA50899B1 (fr) | Composés utiles pour l'inhibition de cdk7 | |
TR201719911A2 (tr) | Raloksi̇fen ve en az bi̇r anti̇psi̇koti̇k ajan i̇çeren kompozi̇syon | |
TN2013000429A1 (en) | Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity |